As R&D productivity declines and the age of blockbuster medicines reaches an end, the pharmaceutical industry is looking at ways to extend the profitable life of its products up to and beyond patent expiry.
16-Feb-2011 - French drugmaker Sanofi Aventis will buy Genzyme after the firms finally agree a valuation based on manufacturing performance, approvals and sales.
09-Feb-2011 - Novasep and instrAction have partnered to develop improved methods for the production of taxane-based active pharmaceutical ingredients (API) citing growing demand for cancer treatments as key driver.
18-Jan-2011 - US CRO INC Research has bought industry consulting group Avos Life Sciences, citing pharma clients’ need to maximize return on R&D and minimize risk as the key driver.
10-Jan-2011 - Cultural diversity within India underpins differing attitudes to oral dose pharmaceutical packaging and this could impact on prescribing habits.
14-Dec-2010 - Pharma should forget about ‘the next blockbuster drug’ and invest more money creating novel drug delivery systems with emerging developers to enhance product value and efficacy, say researchers.
01-Dec-2010 - Novartis will reduce its US General Medicines sales force by 1,400 employees next year in preparation for impending patent loss for key products.
08-Nov-2010 - Celanese has launched a new controlled-release EVA excipient and says developing enhanced formulations is key to a drugmaker’s competitive edge in today’s pharmaceutical market.
28-Oct-2010 - Drug industry demand for chemical intermediates and development projects has rebounded significantly in the last 12 months according to UK group Endeavour Specialty Chemicals.
20-Oct-2010 - Particle Sciences (PSI) becomes provider of Solumer drug delivery tech in deal with Israeli developer SoluBest.
19-Oct-2010 - Prosonix expects high demand for innovative particle processing technologies in the $24bn (€17bn) a-year respiratory pharmaceuticals market over the next few years.
18-Oct-2010 - Data from a study comparing an oral spray formulation of sildenafil citrate to Viagra has been presented by NovaDel Pharma.
13-Oct-2010 - IMS Health predicts that global drug sales will increase 5 to 7 per cent next year, driven by development of innovative pharmaceuticals and growth of emerging markets.
29-Sep-2010 - Venus Remedies is supplying docetaxel to Thailand after a compulsory license was issued to make the drug more affordable.
27-Sep-2010 - Stirling Products is in discussions with three large pharma interesting in accessing its HDA drug delivery platform.
23-Sep-2010 - India’s Sun Pharma has finally acquired a controlling stake in Israeli generics firm Taro Pharmaceutical Industries, significantly expanding its manufacturing capacity in North America.
23-Sep-2010 - Oracle is revising its lifecycle management package to streamline processes including scale-up to commercial production and QbD implementation.
15-Sep-2010 - Q Chip is using new funding to scale up its Q-Sphera technology for cGMP production of sustained release peptide and protein therapeutics.
14-Sep-2010 - Sanofi Pasteur has filed a sBLA with the FDA for an intradermal form of influenza vaccine Fluzone using a microinjection system.
08-Sep-2010 - GSK will work with Lonza on the development of a UK biomanufacturing plant as part of a new MAb manufacturing contract announced today.
08-Sep-2010 - Actavis is looking to enter the biosimilars sector through the proposed acquisition of a stake in Biopartners.
07-Sep-2010 - Indian drugmaker Cipla may invest in South Africa’s Cipla Medpro to boost manufacturing capacity and improve access to rapidly expanding African pharmaceutical markets.
06-Sep-2010 - Colorcon says proximity to emerging drug manufacturing markets was key driver for new Turkey technical service lab.
01-Sep-2010 - NanGenex is introducing GMP bench-top and pilot plant reactors to scale-up its process for the continuous production of nanostructured active ingredients.
31-Aug-2010 - Genzyme has rejected Sanofi-Aventis' $18.5bn (€14.5bn) takeover bid, describing it as offering no improvement in price on the previous proposal and failing “to establish a basis for engagement.”
31-Aug-2010 - Laboratory study shows succinyl-chitosan extended-release (XR) excipient could outperform commercially-available delivery technologies, says Spenser Pharmaceuticals.